A preparation method of caspofungin acetate impurity G
By chemical synthesis of Numoconding B0 and separation and purification of medium and low pressure liquid chromatography columns, high-purity caspofenin acetate impurity G was successfully prepared, which solved the problem of lack of the preparation method of this impurity G in the prior art, and realized The production of high-purity products is suitable for large-scale production.
Patent Information
- Application Number
- CN202010542402.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-06-15
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-06-15
AI Technical Summary
The prior art lacks a method for preparing high-purity caspofenin acetate impurity G, which cannot meet the demand of enterprises and the market for this impurity G as a reference product.
By using Nurmoconding B0 as a raw material, chemical synthesis was performed using reducing agent to obtain caspofenin impurity G crude product, which was then separated and purified by medium and low pressure liquid chromatography column, and lyophilized to obtain caspofenin acetate with a purity of more than 95% by freeze-drying to obtain caspofenin acetate with a purity of more than 95% Fungin Impurity G Solid Powder.
The preparation of high-purity caspofenin acetate impurity G is achieved, which meets market demand, has simple steps and stable conditions, and is suitable for large-scale production.
Smart Images

Figure CN113801202B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of chemistry, and particularly relates to a method for preparing caspofungin acetate impurity G. Background Art
[0002] Caspofungin acetate is the first echinocandin antifungal drug. It was first approved for marketing by the U.S. Food and Drug Administration (FDA) on January 26, 2001. It is mainly used to treat invasive candidiasis, invasive aspergillosis that is refractory or intolerant to other treatments, and empirical treatment of suspected fungal infections in patients with neutropenia and fever. As a representative of a new class of echinocandin antibacterial drugs, caspofungin acetate has obvious advantages in terms of high selectivity, good antibacterial activity, high safety, and low drug resistance.
[0003] Caspofungin acetate is first fermented by Glarea Lozoyensis to obtain a fermentation product, and then the fermentation product is subjected to solid-liquid separation, extraction, adsorption analysis, concentration and drying processes to obtain a crude product of Pneumocandin B0. Then, Pneumocandin B0 is used as a starting material and a series of syntheses are performed to obtain a crude product of caspofungin acetate. The crude product is then crystallized and dried to obtain a finished product of caspofungin acetate API.
[0004] In the synthesis process of crude caspofungin acetate, an isomeric precursor of caspofungin impurity G is produced, and then the caspofungin impurity G is produced through the next reaction. The structure of caspofungin impurity G is shown in formula (III):
[0005]
[0006] In the field of drug testing, caspofungin acetate impurity G is needed as a reference substance.
[0007] Leonard WR, Belyk KM, Conlon DA, et al. Synthesis of the antiifungal β-1, 3-glucan synthase inhibitor CANCIDAS (caspofungin acetate)from pneumocandin B0[J]. The Journal of organic chemistry, 2007, 72(7): 2335-2343. mentioned that the hydroxyl isomerization contributes to the stability of the intermediate, so this configuration will be produced and finally form caspofungin impurity G.
[0008] Currently, there are no other references that specifically report on caspofungin impurity G or caspofungin acetate impurity G. There is also no relevant report on the preparation of high-purity caspofungin acetate impurity G in the prior art. Therefore, it is necessary to develop a method for preparing high-purity caspofungin acetate impurity G to meet the needs of the company itself and the market for caspofungin acetate impurity G reference substances. Summary of the invention
[0009] In order to solve the above technical problems, the present invention provides a method for preparing caspofungin acetate impurity G as shown in formula (I), which specifically comprises the following steps:
[0010]
[0011] 1) Using pneumocandin B0 as raw material, crude caspofungin impurity G was obtained by chemical synthesis;
[0012] 2) dissolving the crude caspofungin impurity G with a solvent to prepare a crude solution and filtering it;
[0013] 3) The filtered crude solution is separated and purified by a chromatographic column in the preparation system, and the eluent is collected;
[0014] 4) freeze-drying the qualified eluate to obtain a solid powder of caspofungin acetate impurity G with a purity of more than 95%.
[0015] Furthermore, in the step 1), pneumocandin B0 is reduced by a reducing agent to obtain a crude impurity G, and the synthesis process is shown in the following equation:
[0016]
[0017] Furthermore, the solvent in step 2) is 0.1% acetic acid aqueous solution, and filtration is performed using a 0.45 μm filter membrane.
[0018] Furthermore, in the step 3), the filtered crude solution of caspofungin impurity G is first placed on a chromatographic column, the chromatographic column is a medium-low pressure liquid chromatography column, the chromatographic column diameter is 30 mm or 50 mm, and the filler of the chromatographic column is SP-100-8-ODS-P; then the chromatographic column is equilibrated with a mobile phase containing 10% ethanol, and the amount of the mobile phase is 2 times the column volume; then, a mobile phase containing 10%-45% ethanol is used for gradient elution, and the amount of the mobile phase is 4 times the column volume; finally, 45%-50% ethanol is used for gradient elution, and the amount of the mobile phase is 8 times the column volume, and the gradient eluate of this stage is collected, and the component in the gradient eluate of this stage is caspofungin acetate impurity G, and HPLC detection is performed.
[0019] Furthermore, in step 3), the flow rate of the eluent is 3-4 times column volume / hour.
[0020] Furthermore, in step 3), the mobile phase consists of mobile phase A and mobile phase B, the sum of their volumes is 100%, wherein mobile phase A is 0.1% acetic acid aqueous solution, and mobile phase B is ethanol.
[0021] Furthermore, in the step 4), the qualified eluate is first frozen, and then the solid eluate is directly sublimated under vacuum to obtain a solid powder of caspofungin acetate impurity G.
[0022] Compared with the prior art, the present invention has the following beneficial effects: 1) The present invention uses the raw material of caspofungin acetate intermediate Pneumocandin B0, and under the action of a reducing agent, reduces the group at a specific position to directly obtain a crude caspofungin impurity G product, and provides a preparation method for the crude caspofungin impurity G product; 2) The present invention uses the crude impurity G product as a raw material, and adopts a preparative chromatography method, adopts a mixed solution of 0.1% acetic acid and ethanol as a mobile phase for isocratic and gradient elution, and finally obtains a solid powder of impurity G with a purity greater than 95%, and provides a preparation method for high-purity caspofungin acetate impurity G, which can meet the requirements of the enterprise itself and the market; 3) The preparation method of the present invention has simple steps, stable conditions, high yield, is suitable for large-scale production, and can meet market demand. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 is a schematic diagram of the preparative chromatography of caspofungin acetate impurity G;
[0024] Figure 2 This is a test diagram of the finished product of caspofungin acetate impurity G in Example 1;
[0025] Figure 3 This is a test diagram of the finished product of caspofungin acetate impurity G in Example 2;
[0026] Figure 4 This is a test diagram of the finished product of caspofungin acetate impurity G in Example 3;
[0027] Figure 5 This is a test diagram of the finished product of caspofungin acetate impurity G in Example 4;
[0028] Figure 6 This is a detection diagram of the finished product of caspofungin acetate impurity G in Example 5. DETAILED DESCRIPTION
[0029] The technical scheme in the embodiment of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiment of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, rather than all. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without making creative work are within the scope of protection of the present invention. The reagents used in the following examples are all commercially available products.
[0030] Example 1
[0031] First, determine the reducing agent, crude solvent, packing material, mobile phase, and elution gradient.
[0032] 1. Determination of reducing agent
[0033] 8g of pneumocandin B0, 1.2g of phenylboronic acid (Phenylboronic Acid) and 200mL of tetrahydrofuran (THF) were mixed and dissolved, heated for dehydration, 5mL of BSTFA (N,O-bis(trimethylsilyl)trifluoroacetamide) was added, and then reduced with a reducing agent. After the reaction was completed, 5mL of hydrochloric acid was used to quench to obtain a crude solution of caspofungin impurity G. The most critical factor in the reaction was the type of reducing agent. Several reducing agents were screened, including: borane tetrahydrofuran, dimethyl sulfide borane, sodium borohydride, and sodium acetate borohydride. The purity of the product of substrate B0 after reduction with different reducing agents was used as an investigation index. After reduction for 1h, the purity (%) of impurity G under different reducing agents is shown in Table 1:
[0034] Table 1 Purity of caspofungin impurity G obtained with different reducing agents
[0035]
[0036] From the above experimental results, it can be seen that when borane tetrahydrofuran (BH3 / THF) is used as a reducing agent, the purity of caspofungin impurity G is the highest, reaching 41%, so the reducing agent is determined to be borane tetrahydrofuran.
[0037] 2. Determination of crude product solvent.
[0038] Since antibiotic products are not stable, it is necessary to select a suitable solvent when dissolving the crude product. The present application screened solvents with different acidity and alkalinity, including: 0.1% acetic acid aqueous solution, 0.5% acetic acid aqueous solution, 0.1% sodium dihydrogen phosphate, 0.5% sodium dihydrogen phosphate, 0.1% disodium hydrogen phosphate, and 0.5% disodium hydrogen phosphate, and dissolved the crude impurities in the above solvents respectively. After standing at room temperature for 48 hours, it was found that impurity G showed different stabilities under different acidity and alkalinity conditions. Under acidic conditions, it showed stronger stability. Among them, the stability was the strongest in 0.1% acetic acid aqueous solution. Therefore, 0.1% acetic acid aqueous solution was selected as the crude product solvent.
[0039] 3. Determination of filler
[0040] According to the characteristics of the product, reverse phase preparative chromatography was used for separation. Through screening of the following C18 fillers, such as SP-120-10-ODS-BP, SP-100-8-ODS-P, and SP-120-30 / 50-ODS-BP, it was found that SP-100-8-ODS-P had the best separation effect and could obtain more than 95% of the fractions. Therefore, SP-100-8-ODS-P was determined as the preparative filler.
[0041] 4. Determination of mobile phase
[0042] (1) Determination of mobile phase A
[0043] Since super antibiotic products generally have poor stability, it is necessary to further investigate the preparation stability of the product. Therefore, the raw material containing a high level of impurity G (41%) was placed in mobile phases with different pH values and the results were observed after being placed at room temperature for 48 hours. The results are shown in Table 2:
[0044] Table 2 Stability study of mobile phase A
[0045]
[0046] According to the results in Table 2: when placed in 0.1% acetic acid aqueous solution, the normalized area of impurity G is almost the same as that of the raw material, and the purity does not change. Therefore, it is determined to use 0.1% acetic acid aqueous solution as mobile phase A.
[0047] (2) Determination of mobile phase B
[0048] Combined with the results of the stability investigation, after using 0.1% acetic acid aqueous solution as phase A, the same column liquid was used, the collection standard was unified to 95%, and then different reverse phases were used for organic solvents (mobile phase B) for investigation, including: acetonitrile, ethanol, methanol, and the highest purity and recovery rate of the collected fractions were used as the investigation indicators. The results are shown in Table 3:
[0049] Table 3 Stability study of mobile phase B
[0050]
[0051] The results are shown in Table 3: When mobile phase B is ethanol, the highest purity in the fraction reaches 97% and the recovery rate reaches 48%, which is higher than acetonitrile and methanol. Therefore, it is determined that the organic phase using an ethanol system has the best effect on impurity separation.
[0052] 5. Determination of elution gradient
[0053] After selecting the filler and mobile phase composition, a rough gradient test was first performed, and it was found that impurity G peaked at about 46% ethanol concentration; the elution program was set to 10% ~ 45% ethanol elution for 4 times the column volume, and then 45% ~ 50% ethanol gradient elution for 8BV was used. Experiments were performed on 30mm and 50mm columns respectively, and it was found that impurity G could be well separated under this elution gradient. The preparative chromatography process is as follows Figure 1 shown.
[0054] In summary, the reducing agent, solvent, filler, mobile phase and elution gradient were determined, and the chromatographic conditions of Example 1 are shown in Table 4.
[0055] Table 4: Chromatographic conditions of Example 1
[0056]
[0057] Preparation of Caspofungin Impurity G Crude Product:
[0058] Take 40g of pneumocandin B0, 6g of phenylboric acid, and 1L of tetrahydrofuran, mix them, add them to a 3L round-bottom flask, heat them in an oil bath at 85°C to remove moisture; when the moisture content is lower than 0.15%, add 25mL of BSTFA to the system and react for 1h; lower the temperature of the system to below -15°C, slowly add 200mL of borane tetrahydrofuran, control the temperature to below -10°C and react for 1h; after the reaction, add 50mL of HCl (1mol / L) to the system to terminate the reaction, remove the solvent from the system, and obtain 18g of crude caspofungin impurity G (solid powder) with a purity of 41%.
[0059] The above reaction was repeated, and the purity of the crude product was about 41%. The crude product of caspofungin impurity G with a purity of 41% was used as the raw material for the next high-purity preparation.
[0060] Preparation of high purity caspofungin acetate impurity G:
[0061] 3 g of crude caspofungin impurity G with a purity of 41% was dissolved in 0.1% acetic acid aqueous solution, and the insoluble matter was removed by filtration with a 0.45 μm filter membrane. The filtered crude G solution was pumped into the chromatographic column of the preparative chromatography. The chromatographic column filler was SP-100-8-ODS-P, the column size was 50 mm*500 mm, the filler particle size was 8 μm, the sample load was 5 g / L, the mobile phase A was 0.1% acetic acid aqueous solution, and the mobile phase B was ethanol. First, a mobile phase containing 10% ethanol, 2 The chromatographic column was equilibrated with a mobile phase containing 10%-45% ethanol and 4 column volumes; then gradient elution was performed with a mobile phase containing 10%-45% ethanol and 4 column volumes; then elution was performed with a mobile phase containing 45%-50% ethanol gradient and 8 column volumes, and the component eluates after 46% ethanol in the elution section were collected. After HPLC detection, it was found that the content of caspofungin acetate impurity G in the collected gradient eluate was above 96%, and 0.65 g of high-purity solid powder of caspofungin acetate impurity G was obtained after freeze-drying, and the total yield of the product was 54%. Figure 2 The detection spectrum shows that the product purity is 95.09%.
[0062] Example 2
[0063] According to the same method and chromatographic conditions as in Example 1, 3.5 g of crude product G with a purity of 41% was dissolved in a 0.1% acetic acid aqueous solution. Finally, the content of caspofungin acetate impurity G in the collected gradient eluate was above 95% in purity. After freeze-drying, 0.7 g of solid powder of caspofungin acetate impurity G was obtained, and the product yield was 50%. Figure 3 As shown in the detection spectrum, the product purity is 97.85%.
[0064] Example 3
[0065] According to the same method and chromatographic conditions as in Example 1, 4 g of crude product G with a purity of 41% was dissolved in a 0.1% acetic acid aqueous solution. Finally, the content of caspofungin acetate impurity G in the collected gradient eluate was above 95% in purity. After freeze-drying, 0.85 g of solid powder of caspofungin acetate impurity G was obtained, and the product yield was 52%. Figure 4 The detection spectrum shows that the product purity is 98.08%.
[0066] Example 4
[0067] According to the same method and chromatographic conditions as in Example 1, 2.5 g of crude product G with a purity of 41% was dissolved in a 0.1% acetic acid aqueous solution. Finally, the content of caspofungin acetate impurity G in the collected gradient eluate was above 95% in purity. After freeze-drying, 0.48 g of solid powder of caspofungin acetate impurity G was obtained. The product yield was 47%. Figure 5 As shown in the detection spectrum, the product purity is 97.70%.
[0068] Example 5
[0069] According to the same method and chromatographic conditions as in Example 1, 5 g of crude product G with a purity of 41% was dissolved in a 0.1% acetic acid aqueous solution. Finally, the content of caspofungin acetate impurity G in the collected gradient eluate was above 95% in purity. After freeze-drying, 1.05 g of solid powder of caspofungin acetate impurity G was obtained, and the product yield was 51%. Figure 6 As shown in the detection spectrum, the product purity is 97.05%.
Claims
1. A method for preparing caspofungin acetate impurity G as shown in formula (I), characterized in that The following steps are involved: 1) Using pneumocandin B0 as a raw material, obtaining a crude product of caspofungin impurity G by chemical synthesis; 2) dissolving the crude caspofungin impurity G with a solvent to prepare a crude solution and filtering the solution; 3) The filtered crude product solution is separated and purified by a chromatographic column in a preparation system, and the eluent is collected; 4) freeze-drying the qualified eluate to obtain a solid powder of caspofungin acetate impurity G with a purity of more than 95%; The solvent in step 2) is 0.1% acetic acid aqueous solution, and filtration is performed using a 0.45 μm filter membrane; in step 3), the filtered crude solution of caspofungin impurity G is firstly placed on a chromatographic column, wherein the chromatographic column is a medium-low pressure liquid chromatography column, the diameter of the chromatographic column is 30 mm or 50 mm, and the filler of the chromatographic column is SP-100-8-ODS-P; then the chromatographic column is equilibrated with a mobile phase containing 10% ethanol, and the amount of the mobile phase is 2 times the column volume; then, gradient elution is performed with a mobile phase containing 10%-45% ethanol, and the amount of the mobile phase is 4 times the column volume; finally, gradient elution is performed with 45%-50% ethanol, and the amount of the mobile phase is 8 times the column volume, and the gradient eluate of this stage is collected and detected by HPLC; In the step 3), the mobile phase consists of mobile phase A and mobile phase B, the sum of their volumes is 100%, wherein mobile phase A is 0.1% acetic acid aqueous solution, and mobile phase B is ethanol.
2. The method for preparing caspofungin acetate impurity G according to claim 1, characterized in that In the step 1), pneumocandin B0 is reduced by a reducing agent to obtain a crude product of caspofungin impurity G. The synthesis process is shown in the following equation:
3. The method for preparing caspofungin acetate impurity G according to claim 1, characterized in that In the step 4), the qualified eluate is first frozen, and then the solid eluate is directly sublimated under vacuum to obtain a solid powder of caspofungin acetate impurity G.
